Literature DB >> 22968517

Preoperative identification of synchronous ovarian and endometrial cancers: the importance of appropriate workup.

Fieke M E Broeders1, Anneke A M van der Wurff, Johanna M A Pijnenborg, M Caroline Vos.   

Abstract

OBJECTIVE: For treatment of patients with both endometrial and ovarian cancer, it is important to discriminate between 2 primary tumors and metastatic disease. Currently, criteria are based on postoperative findings. The aim of this study was to determine whether clinical parameters can discriminate between these groups preoperatively and whether a practical guideline could improve appropriate workup and treatment.
METHODS: A total of 45 patients with a diagnosis of both endometrium and ovarian cancer between 1998 and 2009 and were included for analysis. Clinical and pathological data were obtained, and initial CA-125 was registered; patients had a diagnosis of 2 primary tumors or tumors with metastasis. All patients were reclassified according to workup and treatment.
RESULTS: Patients with synchronous primary tumors were significantly younger, presented more often with abnormal uterine bleeding, and had a lower initial CA-125 than both metastatic groups (P < 0.05). With age and CA-125 included in a polytomic logistic regression model, 83.3% of diagnoses could be classified correctly. In 15 of 17 patients presented with adnexal mass, workup was incomplete owing to lack on information of the endometrial status. In patients presenting with abnormal uterine bleeding, 13 of 21 patients had an incomplete workup leading to staging laparotomy secondary to initial surgical treatment in 2 patients.
CONCLUSIONS: Patients with synchronous endometrial and ovarian cancers are young, often present with abnormal uterine bleeding and have a low initial CA-125. Adequate workup with attention to both ovarian and endometrial status, especially in young patients with a wish to preserve fertility, is important to make the right decision for treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968517     DOI: 10.1097/IGC.0b013e3182679119

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

2.  Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.

Authors:  Casper Reijnen; Heidi V N Küsters-Vandevelde; Marjolijn J L Ligtenberg; Johan Bulten; Marloes Oosterwegel; Marc P L M Snijders; Sanne Sweegers; Joanne A de Hullu; Maria C Vos; Anneke A M van der Wurff; Anne M van Altena; Astrid Eijkelenboom; Johanna M A Pijnenborg
Journal:  Int J Cancer       Date:  2020-02-18       Impact factor: 7.396

3.  Elevated CA-125 Level and ER-Negative as Prognostic Factors for Ovarian Metastasis in Patients with Endometrial Cancer: A Retrospective Cohort Study.

Authors:  Xiaoting Ling; Zheyu Zheng; Jing Xu; Guocai Xu; Hui Zhou; Zhongqiu Lin; Yangyang Li; Jinxiao Liang; Huaiwu Lu
Journal:  Med Sci Monit       Date:  2020-12-25

4.  Comparison of clinicopathologic variables in coexistence cancers of the endometrium and ovary: A review of 55 cases in an academic center in Iran.

Authors:  Hossein Sadidi; Narges Izadi-Mood; Soheila Sarmadi; Fariba Yarandi; Soheila Amini-Moghaddam; Fatemeh Esfahani; Mohammad Sadidi
Journal:  J Res Med Sci       Date:  2015-08       Impact factor: 1.852

5.  Comparison and analysis of the clinicopathological features of SCEO and ECOM.

Authors:  Ting Wang; Xiaodan Zhang; Zhiying Lu; Junyan Wang; Keqin Hua
Journal:  J Ovarian Res       Date:  2019-01-30       Impact factor: 4.234

6.  Uterine involvement in epithelial ovarian cancer and its risk factors.

Authors:  Narges Zamani; Azam Sadat Mousavi; Setare Akhavan; Shahrzad Sheikhhasani; Somayeh Nikfar; Elham Feizabad; Elahe Rezayof; Mitra Modares Gilani
Journal:  J Ovarian Res       Date:  2021-12-07       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.